Wordt geladen...
Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
Denosumab, a human monoclonal antibody, acts against the receptor activator of nuclear factor-κB ligand and is a promising antiresorptive agent in patients with osteoporosis. This study aimed to update the efficacy and safety of denosumab vs. placebo in osteoporosis or low bone mineral density (BMD)...
Bewaard in:
| Gepubliceerd in: | Front Pharmacol |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8080120/ https://ncbi.nlm.nih.gov/pubmed/33935694 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.588095 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|